Breaking News Instant updates and real-time market news.

MRK

Merck

$61.49

-0.35 (-0.57%)

, INTC

Intel

$35.01

-0.16 (-0.45%)

15:05
08/19/17
08/19
15:05
08/19/17
15:05

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. MANUFACTURING COUNCIL: President Donald Trump's American Manufacturing Council was in the spotlight this week as several CEO announced their departures, leading to its dissolvement. The first to announced he was leaving the Forum was Merck's (MRK) Chairman and CEO Kenneth Frazier. "As CEO of Merck and as a matter of personal conscience, I feel a responsibility to take a stand against intolerance and extremism," Fraizer wrote in a tweet. This follows last weekend's tragic events in Charlottesville, Virginia that left one dead and several people injured, and what was seen by many as hesitation from the President to condemn the white supremacists behind the rally. Trump responded to Merck CEO's announcement by tweeting that now he had resigned from the council, there will be more time to "LOWER RIPOFF DRUG PRICES!" Joining Frazier, Intel (INTC) CEO Brian Krzanich and Under Armour (UA; UAA) CEO Kevin Plank also stepped down on Monday from the American Manufacturing Council. Two days later was Campbell (CPB), Johnson & Johnson (JNJ) and United Technologies (UTX) turn to announced their departure. The same day, the President tweeted "Rather than putting pressure on the businesspeople of the Manufacturing Council & Strategy &Policy Forum, I am ending both. Thank you!" The second group, the Strategic and Policy Forum, was led by Blackstone (BX) CEO Stephen Schwarzman, and included names such as JPMorgan (JPM) CEO Jamie Dimon, PepsiCo (PEP) CEO Indra Nooyi, General Motors (GM) CEO Mary Barra, and Wal-Mart (WMT) CEO Doug McMillon. Back in June, Tesla (TSLA) CEO Elon Musk and Disney (DIS) CEO Bob Iger left Trump's Strategic and Policy Forum after the president said he would withdraw from the Paris climate accord. Musk also left Trump's manufacturing council. 2. AMAZON: On Wednesday, President Donald Trump tweeted once again about Amazon (AMZN), saying: "Amazon is doing great damage to tax paying retailers. Towns, cities and states throughout the U.S. are being hurt - many jobs being lost!" 3. HEALTH CARE: According to The Wall Street Journal, the Trump administration said the government will make a set of cost-sharing reduction payments to insurers for August, following threats funding would be stopped after Senate Republicans failed to repeal most of the Affordable Care Act. President Donald Trump has been urged to continue payments, which compensate insurers for reduced out-of-pocket costs for low-income members. Insurers have said they may leave ACA's markets or increase premiums in 2018 without the funding. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). 4. BANNON EXITS WHITE HOUSE: Steve Bannon, the former executive chair of Breitbart News, who had been serving as President Donald Trump's chief strategist, officially resigned on Friday, following weeks of speculation. White House press secretary Sarah Huckabee Sanders said in a statement on Friday, "White House Chief of Staff John Kelly and Steve Bannon have mutually agreed today would be Steve's last day." Sources close to Bannon have said he plans to return to Breitbart News. Joel Pollak, a current senior editor at Breitbart, tweeted the following hashtag after news of Bannon's White House departure: "#WAR". The stock market, which was at highs of the day at the time Bannon's departure was announced, declined throughout the rest of the day and into the weekend. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

MRK

Merck

$61.49

-0.35 (-0.57%)

INTC

Intel

$35.01

-0.16 (-0.45%)

UA

Under Armour

$15.64

-0.64 (-3.93%)

UAA

Under Armour

$17.12

-0.69 (-3.87%)

CPB

Campbell Soup

$53.69

-0.27 (-0.50%)

JNJ

Johnson & Johnson

$132.63

-0.41 (-0.31%)

UTX

United Technologies

$115.48

-0.62 (-0.53%)

BX

Blackstone

$31.52

-0.08 (-0.25%)

JPM

JPMorgan

$90.74

0.09 (0.10%)

GM

General Motors

$34.83

-0.17 (-0.49%)

WMT

Wal-Mart

$79.31

-0.39 (-0.49%)

TSLA

Tesla

$347.46

-4.46 (-1.27%)

DIS

Disney

$100.70

-0.68 (-0.67%)

AMZN

Amazon.com

$958.47

-2.1 (-0.22%)

AET

Aetna

$154.45

-1.36 (-0.87%)

ANTM

Anthem

$191.02

-0.94 (-0.49%)

CNC

Centene

$83.49

-0.13 (-0.16%)

CI

Cigna

$177.03

-1 (-0.56%)

HNT

Health Net

HUM

Humana

$247.28

-0.38 (-0.15%)

MOH

Molina Healthcare

$59.63

0.12 (0.20%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

WCG

WellCare

$173.56

-2.2 (-1.25%)

  • 23

    Aug

  • 24

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 31

    Aug

  • 05

    Sep

  • 06

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 12

    Sep

  • 22

    Sep

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 12

    Oct

  • 08

    Nov

  • 16

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MRK Merck
$61.49

-0.35 (-0.57%)

07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
INTC Intel
$35.01

-0.16 (-0.45%)

08/15/17
BERN
08/15/17
NO CHANGE
BERN
'Alarm bells starting to ring' on Intel, says Bernstein
Bernstein analyst Stacy Rasgon identified a number of negative aspects in Intel's Q2 results, including a year-over-year decline in desktop prices "for the first time in years" and overshipment of notebook PC chips, which she says increases the risk of the company's 2H17 results. Rasgon thinks that the company's 2YH17 datacenter growth targets could be aggressive, and the analyst says that "the quality of Intel's earnings continue to deteriorate." Rasgon says that "alarm bells are starting to ring" on Intel. She keeps a $30 price target and an Underperform rating on the stock.
08/09/17
BNCH
08/09/17
NO CHANGE
BNCH
Buy
CEVA could be pressured by latest in Qualcomm-Apple fight, says Benchmark
Benchmark analyst Gary Mobley noted that Qualcomm (QCOM) announced that the ITC has commenced an investigation into Apple's (AAPL) use of certain mobile devices, radio frequency and processing components" as the companies continue their legal fight over disputed royalties. Intel (INTC) and Qualcomm currently split the iPhone 7 thin modem business and it is expected they'll also evenly split the iPhone 8 business, said Mobley, who noted that CEVA (CEVA) could lose $2M-$2.5M in annual royalties if the Intel-based phones are banned for U.S. import. He keeps a Buy rating on CEVA shares, which are down fractionally in early trading.
07/31/17
DADA
07/31/17
NO CHANGE
DADA
Super Micro has positive read through from Intel comments, says DA Davidson
DA Davidson analyst Mark Kelleher says that comments by Intel (INTC) indicate that its Skylake processor is "on track." The analyst says that there was previously a possibility that the processor would be delayed, and he views the company's latest comments as positive for Super Micro Computer (SMCI). He keeps a $33 price target and a Buy rating on the stock.
08/11/17
ROTH
08/11/17
NO CHANGE
Target $150
ROTH
Neutral
Roth says Nvidia 'stands alone' in semiconductors, valuation 'only question'
Roth Capital analyst Brian Alger said Nvidia's (NVDA) performance over the past several quarters has made it clear that neither Intel (INTC) nor AMD (AMD) have been able to slow the company's growth. Nvidia "stands alone" among semiconductor companies in terms of big volume and big dollar growth potential, but valuation of its stock remains the "only question," according to Alger. He raised his FY19 revenue estimate by roughly $1B and increased his price target on Nvidia shares to $150 from $120, but maintains a Neutral rating on the stock.
UA Under Armour
$15.64

-0.64 (-3.93%)

08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
JEFF
08/02/17
INITIATION
Target $48
JEFF
Buy
Kohl's assumed with a Buy at Jefferies
Jefferies analyst Randal Konik assumed coverage of Kohl's (KSS) with a Buy rating and $48 price target. The analyst views the valuation as attractive amid negative sentiment and left recent store visits encouraged with trends in Active and the "positive reception" for Under Armour (UA, UAA) product.
08/18/17
SBSH
08/18/17
NO CHANGE
Target $81
SBSH
Buy
Foot Locker results and guidance 'greatly disappoints,' says Citi
Citi analyst Kate McShane says Foot Locker's (FL) Q2 results and outlook "greatly disappoints." The company posted its first negative comp since Q4 of 2009, McShane tells investors in a post-earnings research note. Along with Foot Locker, the analyst expects weakness in shares of Nike (NKE) and Finish Line (FINL) as well as Under Armour (UAA, UA) and Dick's Sporting Goods (DKS). McShane currently has a Buy rating on Foot Locker.
08/02/17
SBSH
08/02/17
DOWNGRADE
Target $21
SBSH
Neutral
Under Armour downgraded to Neutral from Buy at Citi
Citi analyst Kate McShane downgraded Under Armour (UAA) and lowered her price target for the shares to $21 from $25. Following yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term," McShane tells investors. She expects the stock will continue trading in a tight range until the end of the year. Under Armour closed yesterday down 9%, or $1.72, to $18.30.
UAA Under Armour
$17.12

-0.69 (-3.87%)

08/02/17
08/02/17
NO CHANGE

KeyBanc becoming 'more constructive' on Under Armour
KeyBanc analyst Edward Yruma says he's becoming "more constructive" on Under Armour (UAA). The analyst says that the company's initiatives can cause its EBIT margins to rise, and he thinks that the company has more margin expansion opportunities in active apparel than lululemon (LULU). However, he thinks the company is still facing "difficult trends," and he keeps a Sector Weight rating.
CPB Campbell Soup
$53.69

-0.27 (-0.50%)

03/21/17
BERN
03/21/17
NO CHANGE
BERN
U.S. food companies downgraded to Underperform at Bernstein
Bernstein analyst Alexia Howard downgraded General Mills (GIS), Kellogg (K), J.M. Smucker (SJM), Conagra Brands (CAG), and Campbell Soup (CPB) to Underperform from Market Perform. As reasons for the downgrades, Howard cited the companies' deteriorating revenue trends and her belief that any takeover premiums for the companies " are unlikely to be particularly high." She adds that activist investors probably won't get involved in the stocks while they are trading at such high valuations. Finally, the analyst believes that the companies are being hurt by consumers' desire for fresher foods and unfavorable shelf space trends at retailers. General Mills target to $52 from $61, Campbell target to $54 from $61, J.M. Smucker target to $130 from $147, Kellogg target to $69 from $83, Conagra target remains $36.
03/21/17
03/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sprouts Farmers Market (SFM) downgraded to Market Perform at BMO Capital. 2. HubSpot (HUBS) downgraded to Outperform from Strong Buy at Raymond James analyst Terry Tilman saying shares have significantly outperformed year-to-date and recommends taking some profits. 3. MEDNAX (MD) downgraded to Neutral from Outperform at Baird analyst Whit Mayo citing a balanced risk/reward, weak organic growth, its sector high historical and relative EBITDA valuation, and a current setup that appears to be reliant on M&A. 4. Cracker Barrel (CBRL) downgraded to Hold from Buy at Argus with analyst John Staszak saying he expects customer traffic to remain weak and same-store sales growth to decelerate over the next several quarters. 5. Conagra Brands (CAG), Kellogg (K), J.M. Smucker (SJM), General Mills (GIS), and Campbell Soup (CPB) were downgraded to Underperform from Market Perform at Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
PIPR
05/24/17
INITIATION
PIPR
Neutral
Campbell Soup initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery initiated Campbell Soup with a Neutral rating and $59 price target, saying he sees flat 3-year average revenue growth and 4%-5% 3-year average EPS growth, driven mostly by margin expansion.
07/26/17
JEFF
07/26/17
NO CHANGE
Target $50
JEFF
Buy
Hain Celestial management would sell at right price, says Jefferies
After hosting investor meetings with management, Jefferies analyst Akshay Jagdale performed additional work to quantify Hain Celestial's (HAIN) strategic value. The analyst believes there would be "significant strategic interest" in Hain and that management "is a willing seller" at the right price. A deal for Hain makes the most sense for Pinnacle Foods (PF), Jagdale tells investors in a research note. He analyzed five scenarios in which hypothetical strategic buyers acquire Hain for $70 per share. The organic and natural products company closed yesterday up 1c to $43.80. Jagdale estimates that by year three, the deal would be 8% accretive to Pinnacle's earnings, 4% to General Mills' (GIS) and Conagra Brands' (CAG), 1.4% to Campbell Soup's and dilutive to Kellogg's (K). The analyst sees limited downside to shares of Hain and keeps a Buy rating on the stock with a $50 price target.
JNJ Johnson & Johnson
$132.63

-0.41 (-0.31%)

08/14/17
BTIG
08/14/17
UPGRADE
Target $100
BTIG
Buy
Masimo upgraded to Buy, could be acquired by Johnson & Johnson, says BTIG
BTIG analyst Sean Lavin upgraded Masimo (MASI) to Buy from Neutral with a $100 price target saying he is more bullish on the Philips (PHG) agreement leading to increased revenue and margins, and the recent share pullback has provided a buying opportunity. Lavin said Masimo has been executing "superbly" and believes the Philips' relationship will drive acceptance of hemoglobin and Rainbow. Further, the analyst thinks Johnson & Johnson (JNJ) could be an acquirer of Masimo as it sells its products into the OR and ICU markets and would "massively" expand operating margins, and notes Philips may see the value of Masimo's products and make a bid.
08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
07/21/17
07/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) was downgraded to Sell from Neutral at BTIG and to Underweight from Neutral at Atlantic Equities. 2. Wells Fargo (WFC) downgraded to Sell from Hold at Berenberg with analyst James Chappell saying the bank's competitive advantages have been eroded. 3. RH (RH) downgraded to Hold from Buy at Deutsche Bank with analyst Adam Sindler citing valuation with the stock up 36% over the past month and 15% this week alone. 4. Union Pacific (UNP) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra saying moderating volumes as well as risks to industrial production in the second half of the year and beyond will limit share upside over the medium term. 5. Check Point (CHKP) downgraded to Neutral from Overweight at Piper Jaffray with analyst Andrew Nowinski saying with the stock up 27% year-to-date, the valuation has now "reached a peak" given the decelerating billings, product/subscription and free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $148
JPMS
Overweight
Johnson & Johnson price target raised ahead of ESC meeting at JPMorgan
JPMorgan analyst Michael Weinstein raised his price target for Johnson & Johnson shares to $148 from $140 ahead of the European Society of Cardiology beginning on August 26. The big event for J&J is the presentation of the COMPASS trial, investigating the use of Xarelto for the treatment of coronary or peripheral artery disease, Weinstein tells investors in a research note. His statistical analysis suggests a minimum 25% reduction in major adverse cardiac events, or MACE. This would make COMPASS a "landmark event in the treatment of CAD/PAD" and lead to Xarelto being adopted as the new standard of care in this greater than $5B indication, Weinstein writes. He recommends buying J&J shares ahead of the European Society of Cardiology meeting and keeps an Overweight rating on the name.
UTX United Technologies
$115.48

-0.62 (-0.53%)

08/07/17
JPMS
08/07/17
NO CHANGE
JPMS
Neutral
JPMorgan views potential Rockwell deal as mixed for United Technologies
JPMorgan analyst C. Stephen Tusa says that at face value, he would view an acquisition of Rockwell Collins (COL) as a "mixed event" for United Technologies (UTX). Benefits include a solid strategic rationale that plays into the broader aerospace sector narrative and some earnings accretion, Tusa tells investors in a research note after Bloomberg reported Friday that United Technologies is mulling the deal. However, the potential size of the acquisitions dilutes the positives somewhat and makes achieving targeted returns a challenge, Tusa contends. He adds that a stock issuance may be required for United Technologies. The analyst has a Neutral rating on the shares.
07/10/17
UBSW
07/10/17
NO CHANGE
Target $135
UBSW
Buy
United Technologies price target raised to $135 from $123 at UBS
UBS analyst David Strauss raised his price target for United Technologies to $135 and keeps a Buy rating on the shares. Higher consensus earnings per share expectations for 2018 to slightly above $7.00 are justified on improving Europe, strong aero aftermarket and a weaker U.S. dollar, Strauss tells investors in a research note. The analyst expects a 2017 guidance raise, but later in the year rather than in Q2.
08/07/17
08/07/17
NO CHANGE

Wells says United Technologies unlikely to buy Rockwell Collins soon
After Bloomberg reported that United Technologies (UTX) is considering buying Rockwell Collins (COL), Wells Fargo calls the timing of its interest "surprising," partly because major airplane makers, including Boeing (BA), are considering moving into avionics and aftermarket as well. The firm thinks that this situation would increase the risk of an acquisition of Rockwell Collins for United Technologies. Wells is "skeptical" that such a deal is "imminent," but estimates that United would pay about $150 per share for Rockwell and says a 100% cash transaction would be 9% accretive for United. Wells keeps Outperform ratings on both stocks.
08/07/17
RBCM
08/07/17
NO CHANGE
RBCM
Rockwell Collins could be acquired for $145 per share, says RBC Capital
After Reuters and Bloomberg reported that United Technologies (UTX) had made an unconfirmed bid to buy Rockwell Collins (COL), RBC Capital analyst Matthew McConnell estimates that Rockwell Collins could be acquired for $145 per share. The analyst says that the deal would strengthen United Technologies and has "ample strategic rationale," although he notes that airplane makers have expressed opposition to similar deals in the past. He adds that the deal "would move" United Technologies "up the technology curve" and enable it to enter the avionics business which he says has high barriers of entry. McConnell thinks that there is a 50% chance of a deal taking place and raised his price target on Rockwell Collins to $133 from $120. He keeps a Sector Perform rating on Rockwell Collins.
BX Blackstone
$31.52

-0.08 (-0.25%)

05/22/17
05/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan with analyst Rod Hall saying while more negative news from the Apple (AAPL) royalty suit is likely, "material fundamental upside" exists from the closure of the NXP Semiconductors (NXPI) by the end of this year. The analyst views the deal as highly accretive. Hall also believes Apple ultimately will want to preserve its commercial relationship with Qualcomm. 2. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at Raymond James with analyst Tavis McCourt saying shares look increasingly attractive based on improved demand visibility that is less economically sensitive than many of its peers, and demand catalysts from FirstNet buildouts that are expected to start in 2018. 3. Entegris (ENTG) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Toshiya Hari citing the recent pullback in shares and maintained a $29 price target. 4. Blackstone (BX) upgraded to Buy from Neutral at Citi with analyst William Katz saying the company's intentions to raise a $40B infrastructure fund should be a "valuation catalyst." 5. Cree (CREE) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he thinks that the company's new CEO could make positive changes at the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/22/17
SBSH
05/22/17
UPGRADE
Target $40
SBSH
Buy
Blackstone upgraded to Buy from Neutral at Citi
Citi analyst William Katz upgraded Blackstone Group to Buy and raised his price target for the shares to $40 from $32. The company's intentions to raise a $40B infrastructure fund should be a "valuation catalyst," the analyst contends.
04/10/17
MSCO
04/10/17
NO CHANGE
Target $36
MSCO
Overweight
Morgan Stanley says to own Blackstone into the Q1 print
Morgan Stanley analyst Michael Cyprys says to buy Blackstone into the Q1 print saying its a best-in-class franchise which saw a number of large transactions close and has unparalleled fundraising ability. Cyprys rates Blackstone an Overweight with a $36 price target.
05/22/17
JMPS
05/22/17
NO CHANGE
JMPS
Blackstone deal with Saudi Arabia positive, says JMP Securities
JMP Securities analyst Devin Ryan says that the new infrastructure investment vehicle that Blackstone launched with the Public Investment Fund of Saudi Arabia may boost the shareholder value of Blackstone by over 10%. The analyst adds that the deal shows that Blackstone "can evolve and innovate," which makes its growth outlook "strong." He keeps a $38 price target and Outperform rating on the shares.
JPM JPMorgan
$90.74

0.09 (0.10%)

07/06/17
07/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) initiated with an Outperform at Raymond James. 2. JPMorgan (JPM) initiated with a Neutral at Goldman Sachs. 3. At Home Group (HOME) initiated with a Buy at SunTrust. 4. Logitech (LOGI) initiated with a Buy at Citi. 5. Medtronic (MDT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/17
GSCO
07/06/17
INITIATION
Target $93
GSCO
Neutral
JPMorgan initiated with a Neutral at Goldman Sachs
Goldman analyst Richard Ramsden resumed coverage on JPMorgan with a Neutral and a $93 price target saying it is a best-in-class franchise with a premium multiple.
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
08/09/17
WELS
08/09/17
INITIATION
Target $110
WELS
Outperform
JPMorgan resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage JPMorgan with an Outperform rating and $110 price target.
GM General Motors
$34.83

-0.17 (-0.49%)

06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/17
MSCO
06/28/17
INITIATION
Target $40
MSCO
Overweight
General Motors resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Adam Jonas resumed coverage on General Motors with an Overweight and a $40 price target. The analyst believes the divestiture of its losing Opel operations could trigger a re-rating in shares and could indicate a willingness by the company to exit other international markets where it can not create value sustainability.
06/21/17
GUGG
06/21/17
INITIATION
Target $37
GUGG
Neutral
General Motors initiated with a Neutral at Guggenheim
Guggenheim analyst Emmanuel Rosner started General Motors with a Neutral rating and $37 price target.
06/13/17
WOLF
06/13/17
INITIATION
Target $33
WOLF
Peer Perform
General Motors initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Chris Bottiglieri initiated General Motors with a Peer Perform and a $33 price target citing competitive risks in key segments, inventory de-stocking, a large presence in a weak China, and high subprime exposure.
WMT Wal-Mart
$79.31

-0.39 (-0.49%)

08/11/17
08/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) upgraded to Overweight from Equal Weight at Stephens with analyst Ben Bienvenu saying that the company's multi-year investments have led to a better in-store experience, which he sees continuing to drive momentum. 2. Kohl's (KSS) upgraded to Neutral from Underperform at Credit Suisse. 3. Huntington Bancshares (HBAN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Kevin Barker saying the "disappointing" expense guidance has lowered expectations while Huntington should grow earnings faster than any regional bank peer in fiscal 2018 and fiscal 2019. 4. Axalta Coating (AXTA) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the 16% pullback over the past three weeks has created an investment opportunity. 5. Perrigo (PRGO) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the quarterly results may mark the beginning of inflection towards stabilization in the Rx business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/17
UBSW
08/18/17
NO CHANGE
Target $84
UBSW
Neutral
Wal-Mart shares fully valued at current levels, says UBS
UBS analyst Michael Lasser said the slight pullback in Wal-Mart shares is more reflective of heightened expectations as opposed to any fundamental change in its long term outlook. He said the company is showing signs of progress in the US with a notable pickup in its grocery section. He also said its ecommerce growth is coming at a considerable cost and he therefore feels the shares are fully valued at current levels. Lasser maintained his Neutral rating and $84 price target on Wal-Mart shares.
08/17/17
BARD
08/17/17
NO CHANGE
Target $85
BARD
Outperform
Wal-Mart posted good quarter with solid comps, says Baird
Baird analyst Peter Benedict says Wal-Mart this morning posted good Q2 results with solid comps that fell generally in-line with consensus expectations. Despite a "somewhat elevated" valuation, the analyst keeps an Outperform rating on the shares due to continued top-line momentum an improving profit profile.
08/11/17
08/11/17
UPGRADE
Target $91

Overweight
Wal-Mart upgraded to Overweight on better in-store experience at Stephens
As previously reported, Stephens analyst Ben Bienvenu upgraded Wal-Mart to Overweight from Equal Weight, stating that the company's multi-year investments have led to a better in-store experience, which he sees continuing to drive momentum. Bienvenu raised his price target on Wal-Mart shares to $91 from $78.
TSLA Tesla
$347.46

-4.46 (-1.27%)

08/17/17
SBSH
08/17/17
NO CHANGE
Target $371
SBSH
Neutral
Tesla price target raised to $371 from $357 at Citi
Citi analyst Itay Michaeli raised his price target for Tesla to $371 while keeping a Neutral rating on the name. The analyst views the company's fundamentals as positive, but still seeks a better risk/reward entry point. His increased price target reflects higher 2017-2020 earnings estimates rise due to lower operating expenses, slightly higher 2019-2020 gross margins and a lower share count.
08/08/17
08/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Argus with analyst William Selesky saying he expects Tesla to reach breakeven two quarters earlier than he'd previously forecast and sees the company achieving full-year profitability in fiscal 2019. 2. L3 Technologies (LLL) upgraded to Buy from Hold at Drexel Hamilton analyst Pete Skibitski saying he is "cautiously" optimistic that there will be a positive resolution in fiscal 2018 budget negotiations, which will benefit the entire space, and notes L3's international outlook has improved as the year has progressed. 3. Foot Locker (FL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying he believes share weakness related to investor concerns surrounding share loss to Amazon (AMZN) and brands' own websites has created an "excellent" buying opportunity. 4. UPS (UPS) upgraded to Buy from Neutral at Citi with analyst Christian Wetherbee saying he sees a "clear path" toward double-digit earnings growth returning in 2018. 5. Cognizant (CTSH) upgraded to Buy from Hold at Berenberg with analyst Georgios Kertsos saying the market now considers U.S. immigration policy changes as unlikely, which leaves upside for investors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/17
BARD
08/14/17
NO CHANGE
Target $411
BARD
Outperform
Tesla price target raised to $411 from $368 at Baird
Baird analyst Ben Kallo raised his price target on Tesla to $411 from $368 as he remains constructive on the company's long-term prospects and the introduction of the Model 3. He believes upcoming catalysts such as the Model 3 ramp will drive the shares higher providing confidence Tesla is not a good short for investors. He believes Tesla Energy may be underappreciated by investors along with the potential total addressable market for the Model 3. Kallo reiterated his Outperform rating on Tesla shares.
08/15/17
GUGG
08/15/17
NO CHANGE
GUGG
Tesla 'can at least approach' positive free cash flow in 2018, says Guggenheim
Guggenheim analyst Robert Cihra estimates that Tesla "can at least approach" positive free cash flow in 2018, before becoming "meaningfully free cash flow positive in 2019 and 2020" due to Model 3 sales. He continues to believe that the company's cash burn peaked in Q2 at more than $900M, and he still thinks that the company will generate positive EPS in 2018. The analyst keeps a $430 price target and a Buy rating on the stock.
DIS Disney
$100.70

-0.68 (-0.67%)

08/14/17
PIPR
08/14/17
NO CHANGE
Target $215
PIPR
Overweight
Piper survey shows Disney loss having minimal impact on Netflix
Piper Jaffray analyst Michael Olson says that while Disney (DIS) ending its agreement for distribution of certain content is a negative headline, it will have minimal impact on the Netflix (NFLX). His firm surveyed over 500 U.S. Netflix subscribers and asked what percent of their Netflix time is spent on Disney. Piper found that "only" around 20% of subscribers spend greater than 10% of their Netflix time viewing Disney content. The analyst expects "almost none" of the remaining 80% of subscribers will cancel due to the loss of Disney. Further, the 20% of heavier Disney viewers are unlikely to cancel unless Disney accounts for a large portion, like greater than 40%, of their Netflix viewing time, Olson tells investors in a research note. He points out that Netflix shares are down 4% since Disney's announcement on August 8. The analyst keeps an Overweight rating on Netflix shares with a $215 price target. The streaming service closed Friday up $2.26 to $171.40.
08/15/17
PIPR
08/15/17
NO CHANGE
Target $130
PIPR
Overweight
Piper survey shows 'sizable' interest in Disney streaming service
Piper Jaffray analyst Stan Meyers says his firm's survey of over 1,000 consumers found a "sizable," 23% interest in subscribing to a Disney/Pixar streaming service. Of those interested, 37% would pay more than $5 per month, Meyers tells investors in a research note. The analyst estimates 4M subscribers will be Disney's (DIS) equilibrium point between launching its own service and licensing to Netflix (NFLX), which will end in 2019. Disney's entry into direct-to-consumer streaming should "unlock some of its library value, enhance leverage with distributors, and open the door to potentially cross sell its consumer products," Meyers argues. He keeps an Overweight rating on Disney shares with a $130 price target. The stock closed yesterday down 59c to $101.40.
08/09/17
NEED
08/09/17
NO CHANGE
NEED
Hold
Needham applauds BAMTech acquisition by Disney
Needham analyst Laura Martin is lowering her 2018 estimates for Disney (DIS), but applauds the BAMTech acquisition as a fast-pass way to escape the U.S. TV-bundle box, albeit expensive as the former said it would be modestly dilutive for 2 years. The analyst believes that every content company must follow CBS (CBS) into the direct-to-consumer channel business to maintain growth. Rather than build it, Disney bought this capability which should accelerate time to market, Martin adds. The analyst reiterates a Hold rating on Disney's shares.
08/18/17
GSCO
08/18/17
NO CHANGE
GSCO
Disney Internet TV service is right strategy, says Goldman Sachs
Goldman Sachs analyst Drew Borst says that Disney's upcoming video streaming service could be dilutive to its profits in the first year before reaching break even in years two and three. However, the analyst says that the move will beat fruit over the long-term because it will allow the company "to develop a more direct relationship with consumers." and monetize "broadband-only U.S. households." The analyst cut his price target on the shares to $119 from $133 but keeps a Buy rating on the stock and keeps the stock on the firm's Conviction Buy List.
AMZN Amazon.com
$958.47

-2.1 (-0.22%)

08/16/17
RHCO
08/16/17
INITIATION
RHCO
Buy
Amazon.com initiated at SunTrust
As noted earlier, SunTrust started coverage of Amazon with a $1,220 price target and a Buy rating. Analyst Youssef Squali says that the company's fundamentals are "compelling," while it has several "sustainable competitive advantages," including its "maniacal focus on the customer and its leveraging of technology innovation." The analyst says that the company is "disrupting the $10T retail industry."
08/16/17
08/16/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL), GoDaddy (GDDY), Wix.com (WIX), Alibaba (BABA), Amazon.com (AMZN), and Priceline (PCLN) were initiated with a Buy at SunTrust, while Snap (SNAP) was initiated with a Sell, and Twitter (TWTR) and eBay (EBAY) were initiated with a Hold. 2. HD Supply (HDS) reinstated with a Neutral at Goldman Sachs. 3. Shiloh Industries (SHLO) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/17/17
BTIG
08/17/17
NO CHANGE
Target $95
BTIG
Buy
BTIG sees Lowe's beating earnings expectations next week
BTIG analyst Alan Rifkin expects Lowe's (LOW) to top earnings expectations when reporting Q2 results next Wednesday, August 23. The analyst's $1.63 estimate is 1c above consensus expectations. He expects a "strong" Q2 comp of 5.5%. Rifkin thinks appliance concerns from Kenmore's agreement to sell through Amazon (AMZN) are overblown and he keeps a Buy rating on Lowe's with a $95 price target.
08/17/17
BWSF
08/17/17
NO CHANGE
Target $14
BWSF
Strong Buy
Barnes & Noble Education 'a weapon' as retailers take on Amazon, says BWS
Barnes & Noble Education (BNED) has become "a weapon" in the fight between traditional brick and mortar retailers and Amazon (AMZN), BWS Financial analyst Vahid Khorsand tells investors in an intraday research note. Target's (TGT) partnership with Barnes & Noble Education to deliver college essentials directly to students "has so far gone unappreciated by the market," the analyst contends. He believes Barnes & Noble Education's earnings report on August 30 could serve as a catalyst for the stock on "multiple fronts." Khorsand has a Buy rating on the name with a $14 price target.
AET Aetna
$154.45

-1.36 (-0.87%)

07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.
ANTM Anthem
$191.02

-0.94 (-0.49%)

07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
CNC Centene
$83.49

-0.13 (-0.16%)

07/26/17
PIPR
07/26/17
NO CHANGE
Target $105
PIPR
Overweight
Piper says double down on Centene, ups target to $105
Piper Jaffray analyst Sarah James attributes yesterday's post-earnings pullback in shares of Centene to the macro backdrop and the company's spending bump that she believes fuels the bear concern that constant spending for growth pressures margins. The analyst "strongly" disagrees and believe this is when investors should double down on Centene shares. The company will see the greatest multiple expansion in the group and has the highest potential for earnings upside, James tells investors in a research note. She raised her price target for the shares to $105 from $85 and keeps an Overweight rating on the name.
06/06/17
MSCO
06/06/17
INITIATION
Target $86
MSCO
Overweight
Centene initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Centene with an Overweight and a $86 price target. The analyst thinks the HealthNet acquisition provides diversification and entry planned expansion in Medicare Advantage could offset potential headwinds.
07/11/17
BERN
07/11/17
NO CHANGE
BERN
Centene price target raised to $100 from $85 at Bernstein
Bernstein analyst Lance Wilkes raised his price target on Centene based on his belief that the managed Medicaid market will grow over the long-term, particularly in long-term care. He keeps an Outperform rating on the stock.
CI Cigna
$177.03

-1 (-0.56%)

06/16/17
06/16/17
NO CHANGE

Leerink reiterates view that Cigna could bid for Humana
Leerink analyst Ana Gupte reiterated his views that Cigna (CI) could make a bid Humana (HUM) following Cigna's disclosure that 60% of its Medicare Advantage plans will be in 4-STAR rated plans. The announcement is most positive for Humana (HUM) which is the largest pure play Medicare Advantage name, but also paves the way for Cigna to potentially dievest its legacy HS Medicare Advantage book and bid for Humana.
HNT Health Net

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$247.28

-0.38 (-0.15%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $250
FBCO
Outperform
Humana price target raised to $250 from $245 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $250 from $245 ahead of Q2 results. He reiterates an Outperform rating on the shares.
08/03/17
PIPR
08/03/17
NO CHANGE
Target $280
PIPR
Overweight
Humana price target raised to $280 from $246 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Humana to $280 saying the company reported a "strong" beat and raise quarter driven by "strong" Medicare Advantage performance and improved cost control. The analyst sees upside to the current share price and keeps an Overweight rating on Humana.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $255
OPCO
Outperform
Humana price target raised to $255 from $236 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $255 from $236 following "strong results" that were driven by outperformance in Medicare Advantage, and after the company raised 2017 EPS guidance. The analyst reiterates an Outperform rating on the shares.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $260
FBCO
Outperform
Humana price target raised to $260 from $250 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $260 from $250 following quarterly results. The analyst reiterates an Outperform rating on the shares.
MOH Molina Healthcare
$59.63

0.12 (0.20%)

08/17/17
08/17/17
UPGRADE
Target $68

Overweight
Molina Healthcare upgraded to Overweight from Underweight at Morgan Stanley
As previously reported, Morgan Stanley upgraded Molina Healthcare two notches to Overweight from Underweight and raised its price target to $68 from $65. Analyst Zack Sopcak sees a clear path to growth from a clear cost cutting plan and strategy, and favorable risk/reward following the 15% decline in shares since June. The analyst believes interim management's clear restructuring targets are achievable and limit share downside. Sopcak said Molina is on the "cusp" of being the next managed care organization to succeed on a turnaround after bottoming out in Q2.
08/17/17
PIPR
08/17/17
NO CHANGE
Target $70
PIPR
Overweight
Molina has sufficient cash without capital raise, says Piper Jaffray
Piper Jaffray analyst Sarah James believes concerns around Molina Healthcare's cash levels, which drove the stock down 5% in the last week, are overdone. After addressing the issue with management, James is "comfortable and confident" that Molina has sufficient cash to meet its needs and has excess reserves without needing an equity raise as feared by bears. The analyst views the shares as undervalued and keeps an Overweight rating on the name with a $70 price target.
07/25/17
LEER
07/25/17
NO CHANGE
Target $80
LEER
Outperform
Leerink remains bullish on Molina Healthcare after job cut announcement
Leerink analyst Ana Gupte continues to have "strong conviction" on Molina Healthcare and reiterates an Outperform rating and a $80 price target after the company's announcement from its interim CEO and CFO Joseph White on the elimination of 1,400 jobs, or 10% of its corporate and health plan workforce. The analyst estimates this could expand margins by over 50 bps or offer 50% net margin expansion and get the company by the end of September to the low end of the stated target of 1.5%-2% net margins.
08/17/17
MSCO
08/17/17
UPGRADE
MSCO
Overweight
Molina Healthcare upgraded to Overweight from Equal Weight at Morgan Stanley
UNH UnitedHealth
$190.82

-1.88 (-0.98%)

08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.
07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
WCG WellCare
$173.56

-2.2 (-1.25%)

06/06/17
MSCO
06/06/17
INITIATION
Target $183
MSCO
Equal Weight
WellCare initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated WellCare with an Equal Weight rating and $183 price target, citing its current valuation.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $163
FBCO
Neutral
WellCare price target raised to $163 from $155 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for WellCare to $163 from $155 ahead of Q2 results. He reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

OFIX

Orthofix

$48.51

-0.49 (-1.00%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Conference/Events
Orthofix management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

ATVI

Activision Blizzard

$64.31

0.11 (0.17%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Periodicals
Activision Blizzard sells esports rights to three additional teams, DJ says »

Activision…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.93

0.475 (1.34%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Options
Pfizer call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

10:45
09/20/17
09/20
10:45
09/20/17
10:45
General news
Euro$ interest rate futures are relatively buoyant »

Euro$ interest rate…

ZLAB

Zai Lab

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NKTR

Nektar

$21.75

-0.85 (-3.76%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Conference/Events
Nektar management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

MAT

Mattel

$15.05

0.18 (1.21%)

, HAS

Hasbro

$94.99

1.75 (1.88%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Hot Stocks
Toymakers in focus after Toys"R"Us files for bankruptcy, Amazon could benefit »

Shares of toymakers,…

MAT

Mattel

$15.05

0.18 (1.21%)

HAS

Hasbro

$94.99

1.75 (1.88%)

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

KKR

KKR

$19.24

0.15 (0.79%)

VNO

Vornado

$73.34

-0.03 (-0.04%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

WMT

Wal-Mart

$80.29

0.24 (0.30%)

JPM

JPMorgan

$94.12

0.18 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 10

    Oct

  • 12

    Oct

  • 22

    Oct

  • 23

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MODN

Model N

$13.35

-0.15 (-1.11%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Conference/Events
Model N management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

MMM

3M

$210.50

-3.06 (-1.43%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Hot Stocks
Analyst says sell 3M amid slowdown in autos, electronics »

JPMorgan downgraded 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ODP

Office Depot

$4.35

-0.07 (-1.58%)

, ADP

ADP

$107.48

0.93 (0.87%)

10:42
09/20/17
09/20
10:42
09/20/17
10:42
Hot Stocks
Office Depot says David Bleisch joins as Chief Legal Officer »

Office Depot (ODP)…

ODP

Office Depot

$4.35

-0.07 (-1.58%)

ADP

ADP

$107.48

0.93 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

10:40
09/20/17
09/20
10:40
09/20/17
10:40
Syndicate
Zai Lab indicated to open at $23, IPO priced at $18 »

Zai Lab (ZLAB) priced 8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

10:40
09/20/17
09/20
10:40
09/20/17
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

APC

Anadarko

$44.64

0.88 (2.01%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JCOM

j2 Global

$73.37

-1.52 (-2.03%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Conference/Events
j2 Global management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

PFE

Pfizer

$35.85

0.4 (1.13%)

, JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

10:34
09/20/17
09/20
10:34
09/20/17
10:34
Hot Stocks
Pfizer takes J&J to court as analysts shake up pharma ratings »

Morgan Stanley analyst…

PFE

Pfizer

$35.85

0.4 (1.13%)

JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

LLY

Eli Lilly

$82.24

0.505 (0.62%)

NVS

Novartis

$86.11

0.26 (0.30%)

ABBV

AbbVie

$86.90

0.53 (0.61%)

BMY

Bristol-Myers

$63.08

0.1532 (0.24%)

AGN

Allergan

$211.28

-3.725 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

  • 18

    Oct

  • 26

    Oct

  • 31

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

PFE

Pfizer

$35.91

0.455 (1.28%)

, PGR

Progressive

$47.57

-0.065 (-0.14%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

PFE

Pfizer

$35.91

0.455 (1.28%)

PGR

Progressive

$47.57

-0.065 (-0.14%)

AAL

American Airlines

$44.38

-0.93 (-2.05%)

LUV

Southwest

$53.77

0.23 (0.43%)

POST

Post Holdings

$86.68

0.32 (0.37%)

NDSN

Nordson

$114.62

0.12 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 18

    Oct

  • 31

    Oct

CELC

Celcuity

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Syndicate
Celcuity opens at $12.35, IPO priced at $9.50 per share »

Celcuity (CELC) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WDC

Western Digital

$89.92

0.74 (0.83%)

, TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

10:28
09/20/17
09/20
10:28
09/20/17
10:28
Recommendations
Western Digital, Toshiba, also use TOSYY analyst commentary  »

Western Digital…

WDC

Western Digital

$89.92

0.74 (0.83%)

TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$81.07

-0.12 (-0.15%)

10:25
09/20/17
09/20
10:25
09/20/17
10:25
Conference/Events
Medtronic has conference call hosted by Leerink »

Leerink to hold a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.